M Catarina Silva

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/201487/publications.pdf

Version: 2024-02-01

19 papers 1,201 citations

623734 14 h-index 19 g-index

24 all docs

24 docs citations

times ranked

24

2011 citing authors

#	Article	IF	CITATIONS
1	Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. ELife, 2019, 8, .	6.0	184
2	Inhibition of p25/Cdk5 Attenuates Tauopathy in Mouse and iPSC Models of Frontotemporal Dementia. Journal of Neuroscience, 2017, 37, 9917-9924.	3.6	117
3	A Genetic Screening Strategy Identifies Novel Regulators of the Proteostasis Network. PLoS Genetics, 2011, 7, e1002438.	3.5	104
4	Neuronal signaling modulates protein homeostasis in <i>Caenorhabditis elegans</i> post-synaptic muscle cells. Genes and Development, 2007, 21, 3006-3016.	5.9	99
5	An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons. Journal of Biological Chemistry, 2017, 292, 19209-19225.	3.4	98
6	Prolonged tau clearance and stress vulnerability rescue by pharmacological activation of autophagy in tauopathy neurons. Nature Communications, 2020, 11, 3258.	12.8	96
7	Human iPSC-Derived Neuronal Model of Tau-A152T Frontotemporal Dementia Reveals Tau-Mediated Mechanisms of Neuronal Vulnerability. Stem Cell Reports, 2016, 7, 325-340.	4.8	92
8	ELAVL4, splicing, and glutamatergic dysfunction precede neuron loss in MAPT mutation cerebral organoids. Cell, 2021, 184, 4547-4563.e17.	28.9	73
9	A Comprehensive Resource for Induced Pluripotent Stem Cells from Patients with Primary Tauopathies. Stem Cell Reports, 2019, 13, 939-955.	4.8	62
10	Human pluripotent stem cell–derived models and drug screening in CNS precision medicine. Annals of the New York Academy of Sciences, 2020, 1471, 18-56.	3.8	54
11	Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies. International Journal of Molecular Sciences, 2020, 21, 8948.	4.1	53
12	Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models. Molecular and Cellular Neurosciences, 2016, 73, 104-115.	2.2	49
13	Neuronal Reprograming of Protein Homeostasis by Calcium-Dependent Regulation of the Heat Shock Response. PLoS Genetics, 2013, 9, e1003711.	3.5	28
14	Dynamic Imaging by Fluorescence Correlation Spectroscopy Identifies Diverse Populations of Polyglutamine Oligomers Formed in Vivo. Journal of Biological Chemistry, 2012, 287, 26136-26145.	3.4	26
15	Targeting Tau Mitigates Mitochondrial Fragmentation and Oxidative Stress in Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2022, 59, 683-702.	4.0	18
16	Exifone Is a Potent HDAC1 Activator with Neuroprotective Activity in Human Neuronal Models of Neurodegeneration. ACS Chemical Neuroscience, 2021, 12, 271-284.	3.5	14
17	Discovery and Optimization of Tau Targeted Protein Degraders Enabled by Patient Induced Pluripotent Stem Cells-Derived Neuronal Models of Tauopathy. Frontiers in Cellular Neuroscience, 2022, 16, 801179.	3.7	14
18	High-content image-based analysis and proteomic profiling identifies Tau phosphorylation inhibitors in a human iPSC-derived glutamatergic neuronal model of tauopathy. Scientific Reports, 2021, 11, 17029.	3.3	8

#	Article	IF	CITATIONS
19	Differentiation of Human Induced Pluripotent Stem Cells into Cortical Neurons to Advance Precision Medicine. Methods in Molecular Biology, 2022, 2429, 143-174.	0.9	2